Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Andrea L.M. Silber"'
Autor:
Marianna Chavez, Jieling Miao, Lajos Pusztai, Matthew P. Goetz, Priya Rastogi, Patricia A. Ganz, Eleftherios (Terry) Mamounas, Soonmyung Paik, Hanna Bandos, Wajeeha Razaq, Anne O’Dea, Virginia Kaklamani, Andrea L.M. Silber, Lisa E. Flaum, Eleni Andreopolu, Joseph Baar, Albert G. Wendt, Jennifer F. Carney, Priyanka Sharma, Julie R. Gralow, Danika L. Lew, William E. Barlow, Gabriel N. Hortobagyi
Publikováno v:
Cancer Research. 83:GS1-07
BACKGROUND: Abnormalities of the PI3kinase/AKT/mTOR signaling network are common in breast cancer (BC) and are associated with endocrine resistance. Everolimus, an mTOR-inhibitor increased PFS when combined with endocrine therapy (ET) in the metastat
Autor:
Leah Ferrucci, Tara B. Sanft, Maura Harrigan, Brenda Cartmel, Fangyong Li, Michelle Zupa, Courtney McGowan, Leah Puklin, Thai Hien Nguyen, Anna M. Tanasijevic, Marian L. Neuhouser, Dawn Hershman, Karen Basen-Engquist, Beth Jones, Tish Knobf, Anees B. Chagpar, Andrea L.M. Silber, Jennifer A. Ligibel, Melinda L. Irwin
Publikováno v:
Cancer Research. 83:PD12-08
Background: Neoadjuvant chemotherapy is available to women with locally advanced breast cancer where chemotherapy is given prior to surgery. By examining resected tissue following neoadjuvant chemotherapy pathological complete response (pCR) can be d
Autor:
Mougalian SS; Sarah S. Mougalian, Lianne N. Epstein, Erin W. Hofstatter, Michael P. DiGiovanna, Andrea L.M. Silber, Kerin Adelson, Lajos Pusztai, and Cary P. Gross, Yale Cancer Center, Yale University; Sarah S. Mougalian, Kerin Adelson, and Cary P. Gross, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, CT; Ami P. Jhaveri, Lancaster General Health, Penn Medicine, Lancaster; Maysa Abu-Khalaf, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Gang Han, Texas A&M University School of Public Health, College Station, TX., Epstein LN; Sarah S. Mougalian, Lianne N. Epstein, Erin W. Hofstatter, Michael P. DiGiovanna, Andrea L.M. Silber, Kerin Adelson, Lajos Pusztai, and Cary P. Gross, Yale Cancer Center, Yale University; Sarah S. Mougalian, Kerin Adelson, and Cary P. Gross, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, CT; Ami P. Jhaveri, Lancaster General Health, Penn Medicine, Lancaster; Maysa Abu-Khalaf, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Gang Han, Texas A&M University School of Public Health, College Station, TX., Jhaveri AP; Sarah S. Mougalian, Lianne N. Epstein, Erin W. Hofstatter, Michael P. DiGiovanna, Andrea L.M. Silber, Kerin Adelson, Lajos Pusztai, and Cary P. Gross, Yale Cancer Center, Yale University; Sarah S. Mougalian, Kerin Adelson, and Cary P. Gross, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, CT; Ami P. Jhaveri, Lancaster General Health, Penn Medicine, Lancaster; Maysa Abu-Khalaf, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Gang Han, Texas A&M University School of Public Health, College Station, TX., Han G; Sarah S. Mougalian, Lianne N. Epstein, Erin W. Hofstatter, Michael P. DiGiovanna, Andrea L.M. Silber, Kerin Adelson, Lajos Pusztai, and Cary P. Gross, Yale Cancer Center, Yale University; Sarah S. Mougalian, Kerin Adelson, and Cary P. Gross, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, CT; Ami P. Jhaveri, Lancaster General Health, Penn Medicine, Lancaster; Maysa Abu-Khalaf, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Gang Han, Texas A&M University School of Public Health, College Station, TX., Abu-Khalaf M; Sarah S. Mougalian, Lianne N. Epstein, Erin W. Hofstatter, Michael P. DiGiovanna, Andrea L.M. Silber, Kerin Adelson, Lajos Pusztai, and Cary P. Gross, Yale Cancer Center, Yale University; Sarah S. Mougalian, Kerin Adelson, and Cary P. Gross, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, CT; Ami P. Jhaveri, Lancaster General Health, Penn Medicine, Lancaster; Maysa Abu-Khalaf, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Gang Han, Texas A&M University School of Public Health, College Station, TX., Hofstatter EW; Sarah S. Mougalian, Lianne N. Epstein, Erin W. Hofstatter, Michael P. DiGiovanna, Andrea L.M. Silber, Kerin Adelson, Lajos Pusztai, and Cary P. Gross, Yale Cancer Center, Yale University; Sarah S. Mougalian, Kerin Adelson, and Cary P. Gross, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, CT; Ami P. Jhaveri, Lancaster General Health, Penn Medicine, Lancaster; Maysa Abu-Khalaf, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Gang Han, Texas A&M University School of Public Health, College Station, TX., DiGiovanna MP; Sarah S. Mougalian, Lianne N. Epstein, Erin W. Hofstatter, Michael P. DiGiovanna, Andrea L.M. Silber, Kerin Adelson, Lajos Pusztai, and Cary P. Gross, Yale Cancer Center, Yale University; Sarah S. Mougalian, Kerin Adelson, and Cary P. Gross, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, CT; Ami P. Jhaveri, Lancaster General Health, Penn Medicine, Lancaster; Maysa Abu-Khalaf, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Gang Han, Texas A&M University School of Public Health, College Station, TX., Silber ALM; Sarah S. Mougalian, Lianne N. Epstein, Erin W. Hofstatter, Michael P. DiGiovanna, Andrea L.M. Silber, Kerin Adelson, Lajos Pusztai, and Cary P. Gross, Yale Cancer Center, Yale University; Sarah S. Mougalian, Kerin Adelson, and Cary P. Gross, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, CT; Ami P. Jhaveri, Lancaster General Health, Penn Medicine, Lancaster; Maysa Abu-Khalaf, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Gang Han, Texas A&M University School of Public Health, College Station, TX., Adelson K; Sarah S. Mougalian, Lianne N. Epstein, Erin W. Hofstatter, Michael P. DiGiovanna, Andrea L.M. Silber, Kerin Adelson, Lajos Pusztai, and Cary P. Gross, Yale Cancer Center, Yale University; Sarah S. Mougalian, Kerin Adelson, and Cary P. Gross, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, CT; Ami P. Jhaveri, Lancaster General Health, Penn Medicine, Lancaster; Maysa Abu-Khalaf, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Gang Han, Texas A&M University School of Public Health, College Station, TX., Pusztai L; Sarah S. Mougalian, Lianne N. Epstein, Erin W. Hofstatter, Michael P. DiGiovanna, Andrea L.M. Silber, Kerin Adelson, Lajos Pusztai, and Cary P. Gross, Yale Cancer Center, Yale University; Sarah S. Mougalian, Kerin Adelson, and Cary P. Gross, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, CT; Ami P. Jhaveri, Lancaster General Health, Penn Medicine, Lancaster; Maysa Abu-Khalaf, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Gang Han, Texas A&M University School of Public Health, College Station, TX., Gross CP; Sarah S. Mougalian, Lianne N. Epstein, Erin W. Hofstatter, Michael P. DiGiovanna, Andrea L.M. Silber, Kerin Adelson, Lajos Pusztai, and Cary P. Gross, Yale Cancer Center, Yale University; Sarah S. Mougalian, Kerin Adelson, and Cary P. Gross, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, CT; Ami P. Jhaveri, Lancaster General Health, Penn Medicine, Lancaster; Maysa Abu-Khalaf, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Gang Han, Texas A&M University School of Public Health, College Station, TX.
Publikováno v:
JCO clinical cancer informatics [JCO Clin Cancer Inform] 2017 Nov; Vol. 1, pp. 1-10.